Biological Markers for Lung Cancer Treatment
Author Information
Author(s): Huang C, Liu D, Masuya D, Nakashima T, Kameyama K, Ishikawa S, Ueno M, Haba R, Yokomise H
Primary Institution: Kagawa University
Hypothesis
Identifying biological markers can improve treatment strategies for resectable non-small-cell lung cancers (NSCLCs).
Conclusion
Biological markers related to tumor angiogenesis and metastasis are useful for detecting aggressive tumors in early-stage NSCLCs.
Supporting Evidence
- Significant prognostic factors included tumor vascularity and various biological markers.
- Patients with TS-negative tumors had better survival rates when treated with UFT.
- High Ki-67 index was associated with poorer survival in stage II-III NSCLCs.
Takeaway
Doctors studied 173 lung cancer patients to find markers that help decide the best treatment. They found some markers that can show how aggressive the cancer is.
Methodology
The study evaluated biological markers in tumor samples using immunohistochemistry and analyzed patient survival data.
Potential Biases
Potential biases due to the retrospective nature of the study and variations in treatment protocols.
Limitations
The study is retrospective and may have biases related to patient selection and treatment variations.
Participant Demographics
{"age":{"median":67,"range":"35-76"},"gender":{"male":116,"female":57},"smoking_habits":{"nonsmoker":65,"smoker":108}}
Statistical Information
P-Value
p<0.01
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website